Age-Related Macular Degeneration&nbsp;
&nbsp;
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, with a profound effect on the quality of life of affected individuals. With the increase in life expectancy bringing growth in the number of reported cases, it adds a significant burden on the healthcare systems with the expensive current standard of care.
AMD's progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both colors and detail, thus compromising the quality of life. Although AMD's exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD.
&nbsp;
Age-Related Macular Degeneration&nbsp; Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">Total Prevalent Cases of Age-Related Macular Degeneration</li>
<li class="ql-align-justify">Total Diagnosed Prevalent Cases of AMD</li>
<li class="ql-align-justify">Type-specific Diagnosed Prevalent Cases of AMD</li>
<li class="ql-align-justify">Total Age-specific Cases of Wet AMD, and Dry AMD</li>
<li class="ql-align-justify">Total Diagnosed Dry AMD Cases by Stages</li>
<li class="ql-align-justify">Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Age-Related Macular Degeneration Epidemiological Insights Observed in the 7MM (2021)</a>
&nbsp;
<ul>
<li class="ql-align-justify">The total incident cases of Age-Related Macular Degeneration observed in the 7MM were observed to be 51 million in the year 2021</li>
<li class="ql-align-justify">The type-specific Age-Related Macular Degeneration diagnosed cases observed in the United States were observed to be wet AMD (approx 4 million) and dry AMD (349 million) in the year 2021</li>
</ul>
&nbsp;
<ul>
<li class="ql-align-justify">The total diagnosed cases of dry AMD by age distribution in the US were observed to be 2 million (50&ndash;59 years), followed by 3 million (60&ndash;69 years), 3 million (70&ndash;79 years), and 2 million (&ge; 80 years) in the year 2021.&nbsp;</li>
<li class="ql-align-justify">The total diagnosed cases of dry AMD by stages in the US were observed to be 10 million (Early and Intermediate) and 1 million (Advanced).&nbsp;</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market" target="_blank" rel="noopener noreferrer">Age-Related Macular Degeneration Market Insight</a>
&nbsp;
<ul>
<li class="ql-align-justify">The market size of Age-Related Macular Degeneration in the 7MM was found to be approximately USD 10 billion in 2021.&nbsp;</li>
</ul>
&nbsp;
<ul>
<li class="ql-align-justify">The market size of wet AMD in the 7MM was found to be approximately USD 8 billion in 2021. &nbsp;</li>
</ul>
&nbsp;
<ul>
<li class="ql-align-justify">The market size of dry AMD in the 7MM was found to be approximately USD 1 billion in 2021. &nbsp;</li>
</ul>
&nbsp;
Age-Related Macular Degeneration Market Strengths&nbsp;
&nbsp;
Extensive research and development have helped us understand the histopathology and pathophysiology of wet AMD.
The dry AMD market has miscellaneous pipelines such as peptide derivatives, antibodies, antisense oligonucleotide, stem cell therapy, and gene therapy which works on a different mechanisms such as C1q, C3, and C5 Inhibitor, Cell replacements, HtrA Serine Peptidase1 inhibitor and other.&nbsp;
&nbsp;
Age-Related Macular Degeneration Market Opportunities
&nbsp;
Several genetic mutations have been identified, which can help develop personalized medicines that can be charged at a premium.
The dry AMD market is untapped till now, and a large and increasing patient pool with no approved or satisfactory therapies provides lucrative opportunities for companies with anticipated potential similar to wet AMD.
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/age-related-macular-degeneration-pipeline-insight" target="_blank" rel="noopener noreferrer">Age-Related Macular Degeneration Emerging Drugs</a>
&nbsp;
The emerging drugs in the Age-Related Macular Degeneration market are
&nbsp;
<ul>
<li class="ql-align-justify"> OPT-302</li>
<li class="ql-align-justify"> KSI-301</li>
<li class="ql-align-justify"> RGX-314</li>
<li class="ql-align-justify"> AKST4290</li>
<li class="ql-align-justify"> GB-102 (Sunitinib Malate)</li>
<li class="ql-align-justify"> RBM-007</li>
<li class="ql-align-justify"> Lytenava (Bevacizumab-vikg)</li>
<li class="ql-align-justify"> UBX1325&nbsp;</li>
<li class="ql-align-justify"> PAN-90806&nbsp;</li>
<li class="ql-align-justify"> CLS-AX (Axitinib), and others</li>
</ul>
&nbsp;
Age-Related Macular Degeneration&nbsp; Key Players&nbsp;
&nbsp;
The key players working in the Age-Related Macular Degeneration market are
&nbsp;
<ul>
<li class="ql-align-justify">Opthea Limited&nbsp;</li>
<li class="ql-align-justify">Kodiak Sciences Inc.&nbsp;</li>
<li class="ql-align-justify">REGENXBIO&nbsp;</li>
<li class="ql-align-justify">Alkahest Inc&nbsp;</li>
<li class="ql-align-justify">Ribomic USA Inc</li>
<li class="ql-align-justify">Unity Biotechnology, Inc</li>
<li class="ql-align-justify">PanOptica, Inc.</li>
<li class="ql-align-justify">Clearside Biomedical</li>
<li class="ql-align-justify">Outlook Therapeutics, Inc.</li>
<li class="ql-align-justify">Graybug Vision, and others</li>
</ul>
&nbsp;
&nbsp;
&nbsp;

Age-Related Macular Degeneration (AMD) Market

Age-Related Macular Degeneration (AMD) Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape